海王英特龙(08329.HK)拟7650万元收购北京中新药业股份51%股权
格隆汇 4 月 22日丨海王英特龙(08329.HK)发布公告,2021年4月22日,买方(深圳海王长健医药有限公司,公司的全资附属公司)与卖方(史新龙、史楠楠及史倩)订立股权转让协议,据此,卖方有条件同意出售目标公司(即北京中新药业股份有限公司)的51%股权,代价为人民币7650万元。收购事项完成后,目标公司将成为公司的非全资附属公司。
目标公司为一间于中国注册成立的有限责任公司,主要从事口服固体制剂的生产。目标公司在研发及制造药品方面拥有数十年经验,现时为中国一家药品制造商。董事会认为,透过收购目标公司,集团将可加强、扩展及多元化发展其于中国研发和制造药品的业务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.